ZYBT // Zhengye Biotechnology Holding Limited (Class A)
FA <GO> NASDAQ RQD COCKPIT → CIK 0001975641 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$1.30 ▼ -0.13
(-9.09%)
MKT CAP: $67.8M • VOL: 122.9K
52W L $1 52W H $8
ZYBT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $16.6M | $25.5M |
| YoY Revenue Growth % | -34.8% | — |
| Gross Profit | $3.4M | $12.5M |
| Gross Margin % | 20.5% | 49.0% |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$10.1M | $2.3M |
| Operating Margin % | -60.6% | 8.8% |
| Net Income (GAAP) | -$10.0M | $1.6M |
| EBITDA (Normalized) | -$10.0M | $3.7M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | $1.9M | $5.6M |
| Capital Expenditures (CapEx) | $144.0K | $1.9M |
| Free Cash Flow (FCF) | $1.8M | $3.8M |
| FCF Margin % | 10.6% | 14.7% |
| Return on Invested Capital (ROIC %) | -22.3% | 4.8% |
| Cash & Short-Term Equivalents | — | $2.5M |
| Total Debt (Short + Long Term) | — | $658.0K |
| Total Stockholders' Equity | $35.7M | $38.9M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZYBT.